About US
Contact us
-
FDA official: Amylin held back safety data on ByettaThe FDA says Amylin Pharmaceuticals hasn't been completely honest about its diabetes drugs. Actually, a top agency official said so back in January, but the documents were only just posted to the FDA2012/6/27
-
Witty: E.U. can avert drug-supply disaster in S. EuropeIs there a way out of the drug-supply mess in cash-strapped European countries? Pharma leaders think so. In a letter to European Union officials, GlaxoSmithKline ($GSK) CEO Andrew Witty urged them to2012/6/26
-
Regulatory headaches replace patent pain, KPMG findsIf there is any benefit to be found by pharma executives in the tightening grip of Congress and regulators that they perceive, it might be that it has taken their minds off patent losses. Or so the la2012/6/26
-
As compulsory licensing spreads, drugmakers adaptThere is the concept associated with evolution that you must adapt or die. Now some experts are suggesting the same thing for drugmakers when it comes to the growing threat of compulsory licensing. N2012/6/25
-
SFDA Commissioner Yin Li meets Cuban Ambassador to ChinaOn the afternoon of June 13, 2012, Yin Li, Commissioner of the State Food and Drug Administration (SFDA), met with the visiting Mr. Alberto Jesús Blanco Silva, the Cuban Ambassador Extraordinary and P2012/6/25
-
Novartis' Afinitor gets nod for breast cancer use by EU committeeNovartis ($NVS) got what it had hoped for Friday, a thumbs up from the EU's Committee for Medicinal Products for Human Use (CHMP) for a new use for its cancer drug Afinitor. The CHMP recommended it fo2012/6/22
-
FDA delivers Xarelto bad news to J&J, BayerThe expected news on Xarelto has been delivered to Johnson & Johnson ($JNJ) and Bayer. In its complete response letter, the FDA turned down their request that it be approved to prevent heart attac2012/6/22
-
Anti-overtime ruling a disguised blessing for reps, recruiters sayThe Supreme Court denied pharma sales reps their overtime. But it may have saved many of their jobs--not to mention their bonuses, industry recruiters say. If the ruling had gone in the reps' favor, d2012/6/21
-
J&J close to $1.5B-plus Risperdal settlement, but not there yetThe latest on Johnson & Johnson's ($JNJ)Risperdal settlement: It may not be as close--or as big--as we previously thought. Then again, it could be bigger. TheThe Wall Street Journal reports that J2012/6/21
-
Roche slashes MabThera price in S. Africa to drive salesDrugmakers are chafing under European price cuts. But more and more, they're cutting prices on their own in the developing world. It's part of the strategy to increase emerging markets sales, a recogn2012/6/20